Skip to content
OpenCapital
Get started

Whitehawk Therapeutics, Inc. Common Stock WHWK Q4 2025 Annual earnings

Reported March 12, 2026 · Before market open

Revenue-Miss by $33.3MDiluted EPS-$0.34Beat by $0.21
Revenue estimate$33.3M
EPS estimate-$0.55

Next report

Aug 6, 2026 (in a month)
EPS estimate-$0.30

Financials

Q4 2025

Income statement

See full
Revenue--100%
Gross profit--100%
Operating income-$24.9M-31.3%
Net income-$23.3M-27.2%
EPS (diluted)-$0.37+45.6%

Balance sheet

See full
Cash & equivalents$37.6M+31.0%
Total equity$136.3M+160%
Total assets$150.8M+114%

Cash flow

See full
Operating cash flow-$17.2M-14.5%
Free cash flow-$17.2M-13.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$114.05M—
P/S16×—

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-1,601.1%-1,985pp
Net margin-288.3%+61.6pp
FCF margin-1,371.4%-1,730pp

Returns & leverage

See full
Return on equity-21.8%-9.2pp
Current ratio10.3×+6.7×

Segments

By segment

See full
Reportable-—

Versus estimates

Revenue

Q1 2025$7.1MQ4 2024$7.2M

Diluted EPS

Q1 2026-$0.32Beat by $0.04
Q4 2025-$0.34Beat by $0.21
Q3 2025-$0.26Beat by $0.25Q2 2025-$0.76Miss by $1.25Q1 2025-$0.36Beat by $0.10Q4 2024-$0.67Miss by $0.45

Ask the moment Whitehawk Therapeutics, Inc. Common Stock reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Whitehawk Therapeutics, Inc. Common Stock report Q4 2025 earnings?
Whitehawk Therapeutics, Inc. Common Stock (WHWK) reported Q4 2025 earnings on March 12, 2026 before market open.
What were Whitehawk Therapeutics, Inc. Common Stock's Q4 2025 revenue and EPS?
Whitehawk Therapeutics, Inc. Common Stock reported revenue of - and diluted EPS of $-0.34 for Q4 2025.
Did Whitehawk Therapeutics, Inc. Common Stock beat estimates in Q4 2025?
Revenue missed the consensus estimate of $33.3M by $33.3M. EPS beat the consensus estimate of $-0.55 by $0.21.
How did Whitehawk Therapeutics, Inc. Common Stock's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $7.2M a year earlier and diluted EPS grew 49.3% from $-0.67.
Where can I find Whitehawk Therapeutics, Inc. Common Stock's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-103117) and the 10-K periodic report (0001193125-26-104158) directly on SEC EDGAR. The filing index links above go to sec.gov.